A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer

American Journal of Obstetrics and Gynecology

Volumn 211, Issue 1, 2014, Pages 68.e1-68.e8

  Krivak, Thomas C ^a   Lele, Shashikant ^c   Richard, Scott ^a   Secord, Angeles Alvarez ^d   Leath, Charles A ^e   Brower, Stacey L ^b   Tian, Chunqiao ^b   Moore, Richard G ^f  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Precision Therapeutics Inc   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d DUKE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f BROWN UNIVERSITY   (United States)

Author keywords

chemoresponse assay; ovarian cancer; platinum resistance

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; ASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORESPONSE ASSAY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; VERY ELDERLY;

CHEMORESPONSE ASSAY; OVARIAN CANCER; PLATINUM RESISTANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84903380646     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2014.02.009     Document Type: Article

References (23)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. R.F. Ozols, B.N. Bundy, and B.E. Greer et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J Clin Oncol 21 2003 194 200
3. A. du Bois, H.J. Luck, and W. Meier et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
4. R.L. Coleman, B.J. Monk, A.K. Sood, and T.J. Herzog Latest research and treatment of advanced-stage epithelial ovarian cancer Nat Rev Clin Oncol 10 2013 211 224
5. N. Katsumata, M. Yasuda, and S. Isonishi et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (JGOG 3016): a randomized, controlled, open-label trial Lancet Oncol 14 2013 1020 1026
6. T.J. Perren, A.M. Swart, and J. Pfisterer et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
7. R.A. Burger, M.F. Brady, and M.A. Bookman et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
8. M.A. Bookman, M.F. Brady, and W.P. McGuire et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup J Clin Oncol 27 2009 1419 1425
9. A. du Bois, B. Weber, and J. Rochon et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J Clin Oncol 24 2006 1127 1135
10. J. Pfisterer, B. Weber, and A. Reuss et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO J Natl Cancer Inst 98 2006 1036 1045
11. T. Rutherford, J. Orr Jr., and E. Grendys Jr. et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer Gynecol Oncol 131 2013 362 367
12. P.M. Bossuyt, J.B. Reitsma, and D.E. Bruns et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration Clin Chem 49 2003 7 18
13. S.L. Brower, J.E. Fensterer, and J.E. Bush The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy G. Mor, A.B. Alvero, Methods in molecular biology. Vol. 414: apoptosis and cancer 2008 Humana Press Inc Totowa, NJ 57 78
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Ovarian cancer: including fallopian tube cancer and primary peritoneal cancer. Version 1.2014. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/ovarian.pdf. Accessed March 7, 2014.
15. M. Markman, and M.A. Bookman Second-line treatment of ovarian cancer Oncologist 5 2000 26 35
16. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
17. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J Clin Oncol 10 1992 513 514
18. F.M. Muggia, P.S. Braly, and M.F. Brady et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115
19. International Collaborative Ovarian Neoplasm Group Paclitaxel plus carboplatin versus standard chemotherapy with either single-Agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomized trial Lancet 360 2002 505 515
20. L.J. Havrilesky, T.C. Krivak, J.W. Mucensku, and E.R. Myers Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer Am J Obstet Gynecol 203 2010 160.e1 160.e7
21. B.J. Monk, T.J. Herzog, and S.B. Kaye et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
22. J. Sehouli, D. Stengel, and G. Oskay-Oezcelik et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 26 2008 3176 3182
23. A. Buda, I. Floriani, and R. Rossi et al. Randomized controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian collaborative study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romangnolo) group Br J Cancer 90 2004 2112 2117